China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Merck’s $2.13B deal with SciBrunch for KRAS G12D inhibitor SPR2015, Abogen’s $7.78B partnership with Novartis for an mRNA T-cell engager, and 3SBio’s ¥1.75B GLP-1 deal with MindRank. Other updates feature AstraZeneca’s $2B investment in Summit, Hengrui’s $2.6B GLP-1/GIP deal…
India Ajay Mahipal of India-focused healthcare impact and venture capital investment platform HealthKois argues that India’s life-sciences ecosystem is approaching an inflection point. Having built its reputation on manufacturing scale, the country now has a narrow window to build the clinical-development capabilities needed to originate and test novel therapies itself. India…
APAC The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather than incremental process tweaks. That growth is already visible on the ground in APAC: AI has moved well beyond the…
Korea Korea’s position as a clinical trials hub did not happen overnight. The country has treated clinical development as a matter of deliberate government policy for the better part of two decades, with Korea ranking among the world’s leading trial destinations as far back as 2018; years before China’s biotech ambitions…
Japan Japan is resetting itself as a clinical trial destination. Costs have halved, local data requirements are being relaxed, and the country is actively courting the global biotechs that have long overlooked it for trials. The opportunity is real; but so is the ground Japan still must make up. Japan’s…
Taiwan Taiwan’s population of just 23 million people and contested political status should, in theory, harm its chances of becoming a globally relevant clinical trials hub. In fact, these two factors – which have forced the island to adopt the most rigorous international standards and build a dense web of global…
China China has rapidly become the world’s leading country for clinical trial volume, alongside the stratospheric growth of its local biotech industry, which now accounts for almost a third of the global drug development pipeline. The high speed and low cost of Chinese trials are unmatched globally. However, in a volatile…
Korea We have set a goal that by 2027, more than 740,000 Korean patients will be benefiting from our treatments Christoph Hamann, General Manager of Merck Healthcare Korea, highlights strong momentum for the affiliate, driven by its fertility and oncology portfolios, as well as an improved access framework for innovative treatments…
Europe Europe accounts for a substantial share of Takeda’s business, hosts a significant slice of the company’s manufacturing footprint, and is involved in around half of its late-stage trials and priority development programmes. As the group prepares potential launches in narcolepsy, psoriasis and polycythaemia vera, a rare blood cancer, Gamze Yuceland explains how patient insight,…
Korea Building stronger bridges between Korean biotech companies and global capital will be critical to unlocking the ecosystem’s full potential Chang Woo Lee, CEO of CUROGEN, discusses translating academic science into innovative medicines, developing multispecific proteins and an oral IBD therapy, and pursuing global expansion. He highlights Korea’s biotech strengths and…
Germany Collaboration across institutions is not optional – it is necessary. The pace and complexity of the challenges demand it. As CEO of TUM University Hospital Munich, Dr med Martin Siess is trying to close a gap that has long dogged German medicine: strong basic research that rarely makes it to…
China Chinese biotechs are now outpacing multinationals at getting drugs into pivotal trials — but MNCs still win the race to final approval. In this piece from the September 2026 edition of DIA Global Forum, Li Wang of Lilly’s China Drug Development & Medical Affairs Center digs into fresh 2023–2025 timeline…
See our Cookie Privacy Policy Here
